Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

International Registry of Flow Diverter Stents (IRF) (IRF)

17 september 2026 uppdaterad av: Montefiore Medical Center

Resultat av flödesavledare för behandling av intrakraniella aneurysm - International Registry of Flow Diverter Stents (IRF)

This multicenter retrospective cohort study aims to evaluate and compare the technical performance, safety, and clinical outcomes of intracranial aneurysms treated with flow diverter stents and endosaccular flow disruptors.

Studieöversikt

Status

Rekrytering

Detaljerad beskrivning

Flow diverters and endosaccular flow disruptors used for the treatment of intracranial aneurysms exhibit distinct procedural and clinical outcomes, with potential differences in device-specific parameters such as procedure time, radiation exposure, adjunct device requirements, and long-term angiographic success. Since the completion of the Pipeline Embolization Device (PED) for the Intracranial Treatment of Aneurysms trial, the field of flow diversion has undergone continuous evolution with the development and approval of several devices. While these devices share a similar mechanism for aneurysm occlusion, their design and delivery systems can vary significantly. Various studies have demonstrated a promising safety and efficacy profile; however, the available data for a direct comparison of the technical and clinical outcomes between these devices remains limited.

The following collaborator is also involved in the research:

Name: Muhammed Amir Essibayi Email: m.amir.essibayi@gmail.com

Studietyp

Observationell

Inskrivning (Beräknad)

5000

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Florida
      • Coral Gables, Florida, Förenta staterna, 33146
        • Rekrytering
        • University of Miami
        • Kontakt:
        • Huvudutredare:
          • Robert M Starke, MD, MS
      • Jacksonville, Florida, Förenta staterna, 32224
        • Avslutad
        • Mayo Clinic Florida
      • Sarasota, Florida, Förenta staterna, 34239
        • Avslutad
        • Sarasota Memorial Research Institute
    • Massachusetts
      • Burlington, Massachusetts, Förenta staterna, 01805
        • Rekrytering
        • Lahey Hospital and Medical Center
        • Kontakt:
        • Huvudutredare:
          • Timo Krings, MD, PhD, MSc
    • Michigan
      • Traverse City, Michigan, Förenta staterna, 49684
        • Rekrytering
        • Munson Medical Center
        • Kontakt:
    • Minnesota
      • Minneapolis, Minnesota, Förenta staterna, 55404
    • New Jersey
      • New Brunswick, New Jersey, Förenta staterna, 08901
        • Rekrytering
        • Robert Wood Johnson University
        • Huvudutredare:
          • Gaurav Gupta, MD
        • Kontakt:
    • New York
      • Buffalo, New York, Förenta staterna, 14068
        • Avslutad
        • University at Buffalo
      • The Bronx, New York, Förenta staterna, 10467
        • Rekrytering
        • Montefiore Medical Center Department of Neurosurgery
        • Huvudutredare:
          • David Altschul, MD
        • Kontakt:
        • Kontakt:
    • Pennsylvania
      • Danville, Pennsylvania, Förenta staterna, 17822
        • Avslutad
        • Geisinger Health
    • Texas
      • Kingwood, Texas, Förenta staterna, 77339
        • Avslutad
        • HCA Houston Healthcare Kingwood
    • Ontario
      • Toronto, Ontario, Kanada, M5B 1W8
      • Toronto, Ontario, Kanada, M5T 2S8
        • Rekrytering
        • Toronto Western Hospital
        • Kontakt:
        • Huvudutredare:
          • Pascal Mosimann, MD, PD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Patients with intracranial aneurysms who underwent endovascular treatment with flow diverter stents or endosaccular flow disruptors

Beskrivning

Inclusion Criteria:

  • Consecutive adult patients (18 years of age or older)

  • Underwent endovascular treatment with one of the following devices:

    a. Endoluminal Flow Diverter Stents: i. Pipeline Flex (Covidien, California, USA) ii. Pipeline Flex with Shield Technology (Covidien) iii. Surpass Streamline (Stryker Neurovascular, California, USA) iv. Surpass Evolve (Stryker) v. Silk flow diverter (Balt Extrusion, Montmorency, France) vi. Flow-Redirection Intraluminal Device (FRED; MicroVention) vii. Flow-Redirection Intraluminal Device X (FRED X; MicroVention) viii. p64 Flow Modulation Device (phenox GmbH) ix. Endovascular clip system (eCLIPs) (eCLIPsTM, eVasc Neurovascular, Vancouver, BC, Canada)

    b. Intrasaccular Flow Disruptors: i. Woven EndoBridge (WEB; MicroVention) ii. Luna/Artisse System (Medtronic) iii. Medina Embolic Device (Medtronic) iv. Contour Neurovascular System (Cerus Endovascular) v. Neqstent Coil Assisted Flow Diverter (Cerus Endovascular) vi. pCONus and pCANvas (phenox GmbH) vii. Nexus Aneurysm Embolization System (EndoStream Medical) viii. CITADEL™ Embolization Device (Balt, USA)

  • Complete medical records and follow-up data available

Exclusion Criteria:

  • Incomplete procedural or follow-up records
  • Non-flow-diverter or non-flow-disruptor treatments (e.g., coiling-only cases)
  • Aneurysms treated with investigational devices not listed within Inclusion Criteria

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: RETROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Endoluminal Flow Diverter Stent

Adults with intracranial aneurysms treated with an endoluminal flow diverter stent as part of routine care.

Intrasaccular Flow Disruptor

Adults with intracranial aneurysms treated with an intrasaccular flow disruptor as part of routine care.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Technical Success
Tidsram: Periprocedurally, up to 24 hours

Technical Success will be determined by successful deployment of the flow diverter stent or endosaccular flow disruptors. A dichotomous determination (i.e., Yes/No) will be made and summarized for this study.

Periprocedurally, up to 24 hours
Procedural Complications following placement
Tidsram: From the time of the procedure up to 1 month post treatment

Procedural complications will be identified as the number of instances of the following adverse clinical events: In-stent Thrombosis/Stenosis; Ischemic complications (Transient Ischemic Attack/Stroke), Intracerebral hemorrhage, Aneurysm rupture, and Vessel occlusion due to flow diverter stent or endosaccular flow disruptor placement.

From the time of the procedure up to 1 month post treatment
Clinical Outcomes at Discharge
Tidsram: Upon study discharge, up to 4 weeks

Clinical outcomes at discharge will be assessed using the modified Rankin Scale (mRS) for neurologic disability. The mRS is a 6-point disability scale with possible scores ranging from 0-5. mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Higher scores are generally associated with less favorable outcomes. For this study patients with an mRS score of 0-2 will be determined to have had a "favorable" outcome to the procedure and patients with an mRS score of 3-5 will have been determined to have had an "unfavorable" outcome.

Upon study discharge, up to 4 weeks
Clinical Outcomes at last available Follow-up
Tidsram: Up to 24 months post procedure

Clinical outcomes at last available follow-up will be assessed using a variant of the modified Rankin Scale (mRS) for neurologic disability. The classic mRS is a 6-point disability scale with possible scores ranging from 0-5. mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Higher scores are generally associated with less favorable outcomes. For this study patients with an mRS score of 0-2 will be determined to have had a "favorable" outcome to the procedure and patients with an mRS score of 3-5 will have been determined to have had an "unfavorable" outcome. Scoring will also include a 6 to identify patients who have expired.

Up to 24 months post procedure
Immediate Angiographic Outcomes at Discharge - O'Kelly-Marotta (OKM) grading scale
Tidsram: Upon study discharge, up to 4 weeks

Immediate Angiographic Outcomes at Discharge will be evaluated using the OKM grading scale. The OKM scale will be used to assess the degree of angiographic filling and in the setting of intracranial aneurysms which were treated by endovascular flow diversion. It is used to predict aneurysm closure over time. Patient outcomes will be stratified based on the following scale scores: Grade A: Total filling (>95% of aneurysm remained); Grade B: Subtotal filling (5-95% of aneurysm remained); Grade C: Entry remnant (<5% aneurysm remained); and Grade D: No filling (0% aneurysm remained). As such, the less aneurysm remnant the more favorable the angiographic outcome. The number/percentage of cases of each OKM Grade will be summarized.

Upon study discharge, up to 4 weeks
Immediate Angiographic Outcomes at Discharge - Modified Raymond-Roy Classification (mRRC)
Tidsram: Upon study discharge, up to 4 weeks

Immediate Angiographic Outcomes at Discharge will also be evaluated using mRRC categorization. mRRC categorization will be used to assess the degree of occlusion achieved when treating an intracranial aneurysm. It categorizes the level of residual contrast filling within an aneurysm after coiling. For purposes of this analysis, Class I will signify complete occlusion; Class II will signify Residual neck occlusion; Class IIIa will signify Residual aneurysm with contrast stasis; and Class IIIb will signify Residual aneurysm without contrast stasis. As such, it is an indicator of how effectively the aneurysm has been sealed off during treatment. The number/percentage of cases of each mRRC category will be summarized.

Upon study discharge, up to 4 weeks
Immediate Angiographic Outcomes at Discharge - WEB Occlusion Scale (WOS)
Tidsram: Upon study discharge, up to 4 weeks

Immediate Angiographic Outcomes at Discharge will be evaluated using the WOS grading scale. The WOS is a standardized angiographic assessment scale for reporting aneurysm occlusion achieved with endosaccular flow disruptors and can be employed to assess the adequacy of treatment. For purposes of this analysis, WOS Grade A will signify complete occlusion; WOS Grade B will signify Residual neck occlusion; and WOS Grade C will signify Residual aneurysm filling. The number/percentage of cases of each WOS grade category will be summarized.

Upon study discharge, up to 4 weeks
Angiographic Outcomes at last available Follow-up - O'Kelly-Marotta (OKM) grading scale
Tidsram: Up to 24 months post procedure

Immediate Angiographic Outcomes at Discharge will be evaluated using the OKM grading scale. The OKM scale will be used to assess the degree of angiographic filling and in the setting of intracranial aneurysms which were treated by endovascular flow diversion. It is used to predict aneurysm closure over time. Patient outcomes will be stratified based on the following scale scores: Grade A: Total filling (>95% of aneurysm remained); Grade B: Subtotal filling (5-95% of aneurysm remained); Grade C: Entry remnant (<5% aneurysm remained); and Grade D: No filling (0% aneurysm remained). As such, the less aneurysm remnant the more favorable the angiographic outcome. The number/percentage of cases of each OKM Grade will be summarized.

Up to 24 months post procedure
Angiographic Outcomes at last available Follow-up - Modified Raymond-Roy Classification (mRRC)
Tidsram: Up to 24 months post procedure

Immediate Angiographic Outcomes at Discharge will also be evaluated using mRRC categorization. mRRC categorization will be used to assess the degree of occlusion achieved when treating an intracranial aneurysm. It categorizes the level of residual contrast filling within an aneurysm after coiling. For purposes of this analysis, Class I will signify complete occlusion; Class II will signify Residual neck occlusion; Class IIIa will signify Residual aneurysm with contrast stasis; and Class IIIb will signify Residual aneurysm without contrast stasis. As such, it is an indicator of how effectively the aneurysm has been sealed off during treatment. The number/percentage of cases of each mRRC category will be summarized.

Up to 24 months post procedure
Angiographic Outcomes at last available Follow-up - WEB Occlusion Scale (WOS)
Tidsram: Up to 24 months post procedure

Immediate Angiographic Outcomes at Discharge will be evaluated using the WOS grading scale. The WOS is a standardized angiographic assessment scale for reporting aneurysm occlusion achieved with endosaccular flow disruptors and can be employed to assess the adequacy of treatment. For purposes of this analysis, WOS Grade A will signify complete occlusion; WOS Grade B will signify Residual neck occlusion; and WOS Grade C will signify Residual aneurysm filling. The number/percentage of cases of each WOS grade category will be summarized.

Up to 24 months post procedure

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Radiation Exposure
Tidsram: Periprocedurally, up to 4 hours

Radiation exposure over the course of the procedure will be extracted and summarized. Radiation exposure will be evaluated based on relevant imaging system metrics used to calculate the total radiation dose delivered to the patient based on the fluoroscopy time and the area of the X-ray field exposed during the procedure. Flow diverter stents and endosaccular flow disruptors typically result in significantly lower radiation exposure compared to other endovascular techniques for treating brain aneurysms due to a reduction in fluoroscopy time and overall reduced radiation dose due to the streamlined nature of the procedures.

Periprocedurally, up to 4 hours
Procedure Duration
Tidsram: Periprocedurally, up to 4 hours

The duration of procedure placement will be extracted and summarized. The duration of the procedure is influenced by the complexity of the aneurysm, the patient's anatomy, and the experience of the interventional radiologist and care team. Shorter procedure duration times are associated with more favorable outcomes.

Periprocedurally, up to 4 hours
Use of Adjunct Devices
Tidsram: Periprocedurally, up to 4 hours

The use of adjunctive devices such as coils, stents or balloons to further enhance aneurysm occlusion of the flow diverter stent or to facilitate positioning and deployment of the endosaccular flow disruptor within the aneurysm sac during the procedure will be extracted and summarized. The number of adjunct devices will be extracted and summarized.

Periprocedurally, up to 4 hours
Recurrence of Aneurysm
Tidsram: 6 to 24 months post procedure

The percentage of patients who experienced aneurysm recurrence will be extracted and summarized based on a binary (Yes/No) determination following retrospective record review. The span of time from initial treatment to recurrence will be assessed and summarized.

6 to 24 months post procedure
Aneurysm Retreatment
Tidsram: 6 to 24 months post procedure

The percentage of patients who required retreatment for a recurrence of aneurysm will be extracted and summarized based on a binary (Yes/No) determination following retrospective record review. The span of time from initial treatment to retreatment will be assessed and summarized.

6 to 24 months post procedure

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 oktober 2023

Primärt slutförande (Beräknad)

1 juli 2027

Avslutad studie (Beräknad)

1 juli 2027

Studieregistreringsdatum

Först inskickad

5 december 2023

Först inskickad som uppfyllde QC-kriterierna

13 december 2023

Första postat (Faktisk)

18 december 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

21 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera